These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27473640)

  • 1. The Pharmacoeconomic Evaluation Process in Ireland.
    McCullagh L; Barry M
    Pharmacoeconomics; 2016 Dec; 34(12):1267-1276. PubMed ID: 27473640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacoeconomic evaluation in Ireland: a review of the process.
    Tilson L; O'Leary A; Usher C; Barry M
    Pharmacoeconomics; 2010; 28(4):307-22. PubMed ID: 20222754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
    McCullagh L; Schmitz S; Barry M; Walsh C
    Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Utility of a Rapid Review Evaluation Process to a National HTA Agency.
    Varley Á; Tilson L; Fogarty E; McCullagh L; Barry M
    Pharmacoeconomics; 2022 Feb; 40(2):203-214. PubMed ID: 34635994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017.
    Usher C; McCullagh L; Tilson L; Barry M
    Pharmacoecon Open; 2019 Dec; 3(4):583-589. PubMed ID: 31073976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland.
    Murphy A; Redmond S
    Value Health; 2019 Apr; 22(4):385-390. PubMed ID: 30975388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective analysis of budget impact models submitted to the National Centre for Pharmacoeconomics in Ireland.
    Lamrock F; McCullagh L; Tilson L; Barry M
    Eur J Health Econ; 2020 Aug; 21(6):895-901. PubMed ID: 32232603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reimbursement of targeted cancer therapies within 3 different European health care systems.
    Mihajlović J; Dolk C; Tolley K; Simoens S; Postma MJ
    Clin Ther; 2015 Feb; 37(2):474-80. PubMed ID: 25638534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Technology Assessment of Drugs in Ireland: An Analysis of Timelines.
    Connolly E; O'Donnell H; Lamrock F; Tilson L; Barry M
    Pharmacoecon Open; 2020 Jun; 4(2):287-296. PubMed ID: 31531843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness evidence on approved cancer drugs in Ireland: the limits of data availability and implications for public accountability.
    Almajed S; Alotaibi N; Zulfiqar S; Dhuhaibawi Z; O'Rourke N; Gaule R; Byrne C; Barry AM; Keeley D; O'Mahony JF
    Eur J Health Econ; 2022 Apr; 23(3):375-431. PubMed ID: 34460007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
    Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
    Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Interaction between Price Negotiations and Heterogeneity: Implications for Economic Evaluations.
    O'Donnell H; McCullagh L; Barry M; Walsh C
    Med Decis Making; 2020 Feb; 40(2):144-155. PubMed ID: 32009545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results-Cost-Effectiveness and Budget Impact Analyses.
    Ornstova E; Sebestianova M; Mlcoch T; Lamblova K; Dolezal T
    Value Health Reg Issues; 2018 Sep; 16():92-98. PubMed ID: 30316030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests.
    Cleemput I; van Wilder P; Huybrechts M; Vrijens F
    Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.